MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro
Authors:
- Jiabei WangJWJiabei Wang
- Tongsen ZhengTZTongsen Zheng
- Xi ChenXCXi Chen
- Hongchi JiangHJHongchi Jiang
- 25 January 2011
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 26 (2) , 371-377
Abstract
Background and Aims: Nutlin‐3, a selective small‐molecule inhibitor of the p53‐MDM2 interaction, has been shown to have antitumor activities in various tumors with wild‐type p53. However, its effect on hepatocellular carcinoma (HCC) with different types of p53 remains unclear. This study is designed to determine nutlin‐3′s antitumor efficacy and underlying mechanisms of action in human HCC cells.Methods: Cell viability assay, cell cycle analysis, apoptosis assay, western blot, co‐ immunoprecipitation and siRNA experiments were analyzed in three human HCC cells. Anti‐tumoral effects of nutlin‐3 targeting the p53 and p73 pathways were evaluated in HCC cell lines.Results: Nutlin‐3 exerted the greatest anti‐tumoral effect to three human HCC cells with wild‐type p53, mutant p53 and p53‐null. Nutlin‐3 not only upregulated p53 in HepG2 cells, but also p73 in Huh7 and Hep3B cells, and disrupted p53‐MDM2 and p73‐MDM2 complexes in HCC cells. The compound inhibited cell proliferation, induced G0/G1 phase arrest, decreased the levels of CyclinD1, CyclinE, CDK2, CDK4, PCNA and E2F‐1, and increased the levels of p21 and p27. It also induced apoptosis, increased the Bax/Bcl‐2 ratio, then activated caspase‐9 and caspase‐3.Conclusions: Nutlin‐3 has significant anticancer effects against human HCC cells, regardless of p53 status, indicating that it is a promising therapy for human hepatocellular carcinoma.Keywords
This publication has 27 references indexed in Scilit:
- Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivoJournal of Hepatology, 2009
- Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of ActionClinical Cancer Research, 2008
- Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradationCell Cycle, 2008
- p73 poses a barrier to malignant transformation by limiting anchorage‐independent growthThe EMBO Journal, 2008
- Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1Oncogene, 2006
- The role of p53 protein family in gastrointestinal malignanciesCell Death & Differentiation, 2006
- An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitorsNature Chemical Biology, 2006
- p63 and p73 are required for p53-dependent apoptosis in response to DNA damageNature, 2002
- mdm-2 gene amplification in 3T3-L1 preadipocytesDifferentiation, 1999
- The p53-mdm-2 autoregulatory feedback loop.Genes & Development, 1993